SEC Comment Letter 0000000000-24-006276 to Structure Therapeutics Inc. (GPCR) (CIK 0001888886) (GPCR)
Structure Therapeutics Inc. (GPCR) (CIK 0001888886)
Date: May 31, 2024 · CIK: 0001888886 · Accession: 0000000000-24-006276
AI Filing Summary & Sentiment
File numbers found in text: 001-41608
Letter
United States securities and exchange commission logo May 31, 2024 Jun Yoon Chief Financial Officer Structure Therapeutics Inc. 601 Gateway Blvd., Suite 900 South San Francisco, California Re:Structure Therapeutics Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-41608 Dear Jun Yoon: We have reviewed your May 24, 2024 response to our comment letter and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our May 22, 2024 letter. Annual Report on Form 10-K Risk Factors Risks Related to Our Reliance on Third Parties We rely on third parties for the manufacture of our product candidates for preclinical and clinical development..., page 82 1.We note your response to prior comment 1. Please revise your proposed disclosure to explain that the current U.S. House of Representatives version of the BIOSECURE Act identifies WuXi AppTec and WuXi Biologics as biotechnology companies of concern and clarify whether WuXi STA is a subsidiary or affiliate of WuXi AppTec and/or WuXi Biologics.
FirstName LastNameJun Yoon Comapany NameStructure Therapeutics Inc. May 31, 2024 Page 2 FirstName LastName Jun Yoon Structure Therapeutics Inc. May 31, 2024 Page 2 Please contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Joshua Gorsky at 202-551-7836 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 31, 2024
Jun Yoon
Chief Financial Officer
Structure Therapeutics Inc.
601 Gateway Blvd., Suite 900
South San Francisco, California
94080
Re:Structure Therapeutics Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-41608
Dear Jun Yoon:
We have reviewed your May 24, 2024 response to our comment letter and have the
following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments. Unless
we note otherwise, any references to prior comments are to comments in our May 22,
2024 letter.
Annual Report on Form 10-K
Risk Factors
Risks Related to Our Reliance on Third Parties
We rely on third parties for the manufacture of our product candidates for preclinical and clinical
development..., page 82
1.We note your response to prior comment 1. Please revise your proposed disclosure to
explain that the current U.S. House of Representatives version of the BIOSECURE Act
identifies WuXi AppTec and WuXi Biologics as biotechnology companies of concern and
clarify whether WuXi STA is a subsidiary or affiliate of WuXi AppTec and/or WuXi
Biologics.
FirstName LastNameJun Yoon
Comapany NameStructure Therapeutics Inc.
May 31, 2024 Page 2
FirstName LastName
Jun Yoon
Structure Therapeutics Inc.
May 31, 2024
Page 2
Please contact Gary Newberry at 202-551-3761 or Lynn Dicker at 202-551-3616 if you
have questions regarding comments on the financial statements and related matters. Please
contact Doris Stacey Gama at 202-551-3188 or Joshua Gorsky at 202-551-7836 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences